Does Insurance Cover Weight Loss Medication?

Why is coverage so inconsistent?

GLP-1 receptor agonists — semaglutide (Wegovy) and tirzepatide (Zepbound) — are among the most expensive medications on the market, with monthly list prices often exceeding $1,000. Employers and insurers have been sharply divided on whether to cover them. Some plans cover them broadly for people who meet clinical criteria (BMI thresholds, weight-related conditions); others explicitly exclude all drugs labeled for weight management. Coverage rules have been shifting rapidly as data on cardiovascular and other benefits accumulates 1Ref 1National Institute of Diabetes and Digestive and Kidney Diseases (2023).Prescription Medications to Treat Overweight and Obesity.Overview of GLP-1 eligibility criteria, prior authorization requirements, the role of obesity medicine specialists, and FDA concerns about compounded versions.

Does the diagnosis on the prescription affect coverage?

Yes, significantly. Insurance coverage often depends on what diagnosis is submitted with the prescription, not just which drug is prescribed.

Ozempic (semaglutide) prescribed for type 2 diabetes is far more broadly covered than Wegovy (the same molecule at a higher dose) prescribed for obesity. Similarly, Mounjaro (tirzepatide) prescribed for type 2 diabetes is often covered when Zepbound (same molecule, weight-management indication) is not.

Your clinician's office manages prior authorization forms and can navigate how your diagnoses are documented. This matters.

What is a prior authorization and how does it work?

Even when a plan covers weight-loss medications, prior authorization (PA) is almost always required. Your clinician submits documentation to the insurer showing you meet criteria — typically BMI, documented weight-related conditions, and often evidence that lifestyle interventions have been tried. The insurer reviews this before the pharmacy will dispense the medication at the covered price.

PA processes vary by insurer and can take days to weeks. If the request is denied, an appeal process exists. Clinicians often help with appeals, and a well-documented letter of medical necessity can change the outcome 1Ref 1National Institute of Diabetes and Digestive and Kidney Diseases (2023).Prescription Medications to Treat Overweight and Obesity.Overview of GLP-1 eligibility criteria, prior authorization requirements, the role of obesity medicine specialists, and FDA concerns about compounded versions.

What about Medicare and Medicaid?

Medicare Part D has historically been statutorily prohibited from covering drugs prescribed specifically for weight loss — a restriction established under the Medicare Modernization Act of 2003. However, this is evolving. Starting July 2026, CMS launched the Medicare GLP-1 Bridge demonstration, which provides temporary Part D coverage of Wegovy and Zepbound for eligible beneficiaries (BMI ≥35, or ≥27 with qualifying conditions) at a $50 copayment 2Ref 2Cubanski J, KFF (Kaiser Family Foundation) (2026).What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries.Medicare GLP-1 Bridge demonstration (July 2026): temporary Part D coverage of Wegovy and Zepbound; Medicaid coverage by state as of 2026; Medicare statutory exclusion background. Semaglutide was also selected for Medicare drug price negotiation in 2025, with a negotiated price set to take effect in 2027.

Medicaid coverage varies by state. As of early 2026, approximately 13 state Medicaid programs cover GLP-1s for obesity treatment, while several states have dropped or restricted coverage due to budget concerns 2Ref 2Cubanski J, KFF (Kaiser Family Foundation) (2026).What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries.Medicare GLP-1 Bridge demonstration (July 2026): temporary Part D coverage of Wegovy and Zepbound; Medicaid coverage by state as of 2026; Medicare statutory exclusion background. If you are on Medicare or Medicaid, ask your clinician's office or call your insurer directly for the current rules.

What are my options if my insurance does not cover it?

Several paths are worth exploring:

• Manufacturer patient assistance programs — Novo Nordisk and Eli Lilly each offer programs for eligible patients. Eligibility rules are income-based and listed on their official websites. These typically do not apply to Medicare or Medicaid.
• Insurance appeal — A denial is not final. A letter of medical necessity from your clinician, with documented weight-related conditions, has succeeded for many patients on appeal.
• Alternative medications — Your clinician may know which medication in the same class has better coverage under your specific plan.
• Employer HR review — Some employers add weight-management drug coverage when employees request it through benefits review.
• Telehealth weight-management services — Some include medication access as part of a bundled program.

On compounded semaglutide: Compounded versions became widely available during the branded drug shortage period. The FDA has raised quality and safety concerns about compounded versions, and their legal status is subject to ongoing regulatory change. Ask your clinician for the current situation before pursuing this path 1Ref 1National Institute of Diabetes and Digestive and Kidney Diseases (2023).Prescription Medications to Treat Overweight and Obesity.Overview of GLP-1 eligibility criteria, prior authorization requirements, the role of obesity medicine specialists, and FDA concerns about compounded versions.